Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography

Journal of Clinical Gastroenterology

Volumn 42, Issue 7, 2008, Pages 839-843

  Masuzaki, Ryota ^a   Tateishi, Ryosuke ^a   Yoshida, Haruhiko ^a,b   Yoshida, Hideo ^a   Sato, Shinpei ^a   Kato, Naoya ^a   Kanai, Fumihiko ^a   Sugioka, Yosuke ^a   Ikeda, Hitoshi ^a   Shiina, Shuichiro ^a   Kawabe, Takao ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Liver fibrosis; Receiver operating characteristics (ROC); Stratum specific likelihood ratio (SSLR)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; PROTHROMBIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ELASTOGRAPHY; FEMALE; GENDER; GROUPS BY AGE; HEPATITIS C; HUMAN; LIVER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RIGIDITY; RISK ASSESSMENT; THROMBOCYTE COUNT; ELASTICITY; EVALUATION; LIVER CIRRHOSIS; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; ROC CURVE; STATISTICAL MODEL;

AGED; CARCINOMA, HEPATOCELLULAR; CROSS-SECTIONAL STUDIES; ELASTICITY; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIKELIHOOD FUNCTIONS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK ASSESSMENT; ROC CURVE;

EID: 53749083585     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318050074f     Document Type: Article

References (29)

1. Seeff LB. Introduction: the burden of hepatocellular carcinoma. Gastroenterology. 2004;127(5 suppl 1):S1-S4.
2. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127(5 suppl 1):S17-S26.
3. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol. 2003;38(suppl 1):S136-S149.
4. Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ. 1992;120:45-173.
5. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97-104.
6. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-524.
7. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.
8. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349: 825-832.
9. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174-181.
10. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002;36(5 suppl 1):S152-S160.
11. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705-1713.
12. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41:48-54.
13. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343-350.
14. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55:403-408.
15. Kazemi F, Kettaneh A, N'Kontchou G, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol. 2006;45:230-235.
16. Torzilli G, Minagawa M, Takayama T, et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology. 1999;30:889-893.
17. Foucher J, Castera L, Bernard PH, et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol. 2006;18:411-412.
18. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.
19. Beck JR. Likelihood ratios. Another enhancement of sensitivity and specificity. Arch Pathol Lab Med. 1986;110:685-686.
20. Radack KL, Rouan G, Hedges J. The likelihood ratio. An improved measure for reporting and evaluating diagnostic test results. Arch Pathol Lab Med. 1986;110:689-693.
21. Furukawa TA, Goldberg DP, Rabe-Hesketh S, et al. Stratumspecific likelihood ratios of two versions of the general health questionnaire. Psychol Med. 2001;31:519-529.
22. Peirce JC, Cornell RG. Integrating stratum-specific likelihood ratios with the analysis of ROC curves. Med Decis Making. 1993;13: 141-151.
23. Velazquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003;37:520-527.
24. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-1801.
25. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25:754-758.
26. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991; 325:675-680.
27. Peng YC, Chan CS, Chen GH. The effectiveness of serum alphafetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepatogastroenterology. 1999;46:3208-3211.
28. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alphafetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570-575.
29. Fagan TJ. Letter: Nomogram for Bayes theorem. N Engl J Med. 1975;293:257.